share_log

Ningbo David Medical Device (SZSE:300314) Jumps 24% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

Ningbo David Medical Device (SZSE:300314) Jumps 24% This Week, Though Earnings Growth Is Still Tracking Behind Five-year Shareholder Returns

寧波大衛醫療器械(深圳證券交易所代碼:300314)本週上漲24%,儘管收益增長仍落後於五年股東回報
Simply Wall St ·  05/08 18:03

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. Buying under-rated businesses is one path to excess returns. For example, long term Ningbo David Medical Device Co., Ltd. (SZSE:300314) shareholders have enjoyed a 57% share price rise over the last half decade, well in excess of the market return of around 14% (not including dividends).

一般而言,積極選股的目的是尋找回報優於市場平均水平的公司。收購被低估的企業是獲得超額回報的一種途徑。例如,寧波戴維醫療器械有限公司(深交所股票代碼:300314)的長期股東在過去五年中股價上漲了57%,遠遠超過了約14%的市場回報率(不包括股息)。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在過去一週強勁上漲之後,值得一看的是長期回報是否是由基本面改善推動的。

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

用本傑明·格雷厄姆的話來說:從短期來看,市場是一臺投票機器,但從長遠來看,它是一臺稱重機。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

During five years of share price growth, Ningbo David Medical Device achieved compound earnings per share (EPS) growth of 43% per year. The EPS growth is more impressive than the yearly share price gain of 9% over the same period. So one could conclude that the broader market has become more cautious towards the stock.

在五年的股價增長中,寧波戴維醫療器械實現了每年43%的複合每股收益(EPS)增長。每股收益的增長比同期9%的年度股價增長更令人印象深刻。因此,人們可以得出結論,整個市場對該股變得更加謹慎。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到 EPS 隨時間推移的變化(點擊圖表查看確切值)。

earnings-per-share-growth
SZSE:300314 Earnings Per Share Growth May 8th 2024
SZSE: 300314 每股收益增長 2024 年 5 月 8 日

This free interactive report on Ningbo David Medical Device's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

如果你想進一步調查該股,這份關於寧波戴維醫療器械收益、收入和現金流的免費互動報告是一個很好的起點。

What About Dividends?

分紅呢?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Ningbo David Medical Device, it has a TSR of 64% for the last 5 years. That exceeds its share price return that we previously mentioned. This is largely a result of its dividend payments!

重要的是要考慮任何給定股票的股東總回報率和股價回報率。股東總回報率是一種回報計算方法,它考慮了現金分紅的價值(假設收到的任何股息都經過再投資)以及任何貼現資本籌集和分拆的計算價值。因此,對於支付豐厚股息的公司來說,股東總回報率通常遠高於股價回報率。以寧波戴維醫療器械爲例,在過去的5年中,其股東回報率爲64%。這超過了我們之前提到的其股價回報率。這在很大程度上是其股息支付的結果!

A Different Perspective

不同的視角

We regret to report that Ningbo David Medical Device shareholders are down 29% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 8.9%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. On the bright side, long term shareholders have made money, with a gain of 10% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Ningbo David Medical Device better, we need to consider many other factors. To that end, you should learn about the 2 warning signs we've spotted with Ningbo David Medical Device (including 1 which is significant) .

我們遺憾地報告,寧波戴維醫療器械的股東今年下跌了29%(甚至包括股息)。不幸的是,這比整個市場8.9%的跌幅還要嚴重。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本發展。好的一面是,長期股東賺了錢,在過去的五年中,每年增長10%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。長期跟蹤股價表現總是很有意思的。但是,要更好地了解寧波戴維醫療器械,我們需要考慮許多其他因素。爲此,你應該了解我們在寧波戴維醫療器械上發現的兩個警告信號(包括一個重要的警告信號)。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果你想看看另一家公司——一家財務狀況可能優異的公司——那麼千萬不要錯過這份已經證明自己可以增加收益的公司的免費名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論